Integrating oral PrEP delivery among African women in a large HIV endpoint‐driven clinical trial
Open Access
- 12 May 2020
- journal article
- research article
- Published by Wiley in Journal of the International AIDS Society
- Vol. 23 (5), e25491
- https://doi.org/10.1002/jia2.25491
Abstract
Introduction Global guidelines emphasize the ethical obligation of investigators to help participants in HIV‐endpoint trials reduce HIV risk by offering an optimal HIV prevention package. Oral pre‐exposure prophylaxis (PrEP) has increasingly become part of state‐of‐the‐art HIV prevention. Here we describe the process of integrating oral PrEP delivery into the HIV prevention package of the Evidence for Contraceptive Options and HIV Outcomes (ECHO) Trial. Methods ECHO was an open‐label randomized clinical trial that compared HIV incidence among women randomized to one of three effective contraceptives. In total, 7830 women aged 16 to 35 years from 12 sites in four African countries (Eswatini, Kenya, South Africa and Zambia) were enrolled and followed for 12 to 18 months, from 2015 to 2018. Part‐way through the course of the trial, oral PrEP was provided to study participants either off‐site via referral or on site via trained trial staff. PrEP uptake was compared between different contraceptive users using Chi‐squared tests or t‐tests. HIV seroincidence rates were compared between participants who never versus ever initiated PrEP using exact Poisson regression. Results PrEP access in ECHO began through public availability in Kenya in May 2017 and was available at all sites by June 2018. When PrEP became available, 3626 (46.3%) eligible women were still in follow‐up in the study, and of these, 622 (17.2%) initiated PrEP. Women initiating PrEP were slightly older; more likely to be unmarried, not living with their partner, having multiple partners; and less likely to be earning their own income and receiving financial support from partners (all p < 0.05). PrEP initiation did not differ across study randomized groups (p = 0.7). Two‐thirds of PrEP users were continuing PrEP at study exit. Conclusions There is a need for improved HIV prevention services in clinical trials with HIV endpoints, especially trials among African women. PrEP as a component of a comprehensive HIV prevention package provided to women in a large clinical trial is practical and feasible. Provision of PrEP within clinical trials with HIV outcomes should be standard of prevention.Funding Information
- South African Medical Research Council
- United States Agency for International Development
- United Nations Population Fund
- Bill and Melinda Gates Foundation (OPP1032115)
This publication has 10 references indexed in Scilit:
- Integrating oral PrEP delivery among African women in a large HIV endpoint‐driven clinical trialJournal of the International AIDS Society, 2020
- HIV pre‐exposure prophylaxis for adolescent girls and young women in Africa: from efficacy trials to deliveryJournal of the International AIDS Society, 2019
- HIV incidence among women using intramuscular depot medroxyprogesterone acetate, a copper intrauterine device, or a levonorgestrel implant for contraception: a randomised, multicentre, open-label trialThe Lancet, 2019
- Taking stock of the present and looking ahead: envisioning challenges in the design of future HIV prevention efficacy trialsThe Lancet HIV, 2019
- Rationale and design of a multi-center, open-label, randomised clinical trial comparing HIV incidence and contraceptive benefits in women using three commonly-used contraceptive methods (the ECHO study)Gates Open Research, 2018
- An Empiric HIV Risk Scoring Tool to Predict HIV-1 Acquisition in African WomenJAIDS Journal of Acquired Immune Deficiency Syndromes, 2016
- Tenofovir-Based Preexposure Prophylaxis for HIV Infection among African WomenThe New England Journal of Medicine, 2015
- Ethical considerations in determining standard of prevention packages for HIV prevention trials: examining PrEP.Developing World Bioethics, 2013
- Antiretroviral Prophylaxis for HIV Prevention in Heterosexual Men and WomenThe New England Journal of Medicine, 2012
- Preexposure Prophylaxis for HIV Infection among African WomenThe New England Journal of Medicine, 2012